Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Biotech-Focused China Fund Invests UP to $10M in Novel Therapeutics, Also Open to Diagnostics Companies Across North America

16 May

A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices or Digital Health companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: USA Investment Firm with Ties to China Seeks Opportunities Across Disruptive Drugs, Devices, Diagnostics, and Digital Health Technologies

16 May

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Family Office Makes Seed Investments in All Life Science Sectors, with Strongest Interest in Medtech Technologies

16 May

A family office that has been actively investing for several years, is supported by well-established Chinese partners and supports companies in venturing globally. To date, the firm has made over 20 investments, mostly in the medical device space. The firm focuses on making seed investments up to $500K, with $200K being the average check size. The firm is open to global opportunities.

The firm invests across all sectors of life sciences, including therapeutics, medical devices, diagnostics, and digital health, with most of its investments having been in medtech companies. The firm is technology agnostic and is open to all kinds of high potential opportunities.

The firm seeks to work with management teams with strong academic credentials and significant experience in successfully launching early-stage ventures. The firm prefers to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: